Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

• Graham R. Foster ,

  * E-mail: g.r.foster@qmul.ac.uk

  Affiliation Institute of Cellular and Molecular Sciences, Queen Mary University of London, London, United Kingdom

  ⨯
• Carmine Coppola,

  Affiliation Unità Operativa Epatologia ed Ecografia Interventistica Ospedale Gragnano, Naples, Italy

  ⨯
• Moutaz Derbala,

  Affiliation Hamad Medical Hospital, Doha, Qatar

  ⨯
• Peter Ferenci,

  Affiliation Medical University of Vienna, Vienna, Austria

  ⨯
• Alessandra Orlandini,

  Affiliation Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

  ⨯
• K. Rajender Reddy,

  Affiliation University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯
• Ludovico Tallarico,

  Affiliation Divisione di Medicina, Ospedale Elena D’Aosta, Naples, Italy

  ⨯
• Mitchell L. Shiffman,

  Affiliation Liver Institute of Virginia, Bon Secours Health System, Newport News/Richmond, Virginia, United States of America

  ⨯
• Silke Ahlers,

  Affiliation PROMETRIS GmbH, Mannheim, Germany

  ⨯
• Georgios Bakalos,

  Affiliation F. Hoffmann-La Roche, Basel, Switzerland

  ⨯
• Tarek Hassanein,

  Affiliation University of California San Diego, San Diego, California, United States of America

  ⨯
• GUARD-C Study Group

  ¶Membership of the GUARD-C Study Group is provided in the Acknowledgments.

  ⨯